June 26, 2020 -- Celltex has received approval from the U.S. Food and Drug Administration (FDA) to investigate the prophylactic efficacy of autologous adipose tissue-derived mesenchymal stem cells (ADMSCs) against COVID-19.
Celltex Therapeutics received FDA approval for a phase II clinical trial using mesenchymal stem cells (MSCs) as a prophylactic against COVID-19. Image courtesy of Celltex.
The company will initiate a phase I multicenter, randomized, double-blind, placebo-controlled study to evaluate ADMSCs. The study will enroll 200 patients who have never been infected with COVID-19. It will evaluate the overall safety of ADMSCs and demonstrate their efficacy as a prophylactic drug for those at high risk of becoming infected by the virus.
Copyright © 2020 scienceboard.net